EUR 115.30 at Lang & Schwarz: Drägerwerk stock pre-market minus 0.26 percent versus the Xetra close
Published on 10/14/2026 at 08:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOutlook and valuation signals
- Fiscal 2026 is Drägerwerk’s published outlook period.
- The next round-number level is EUR 116.00, or plus 0.61 percent from the current price.
- Drägerwerk stock trades pre-market at EUR 115.30 at 8:25 a.m. CEST at Lang & Schwarz on October 14, 2026, minus 0.26 percent versus the Xetra close of October 13, 2026.
Drägerwerk stock is at EUR 115.30 at Lang & Schwarz at 8:25 a.m. CEST on October 14, 2026, down EUR 0.30 or minus 0.26 percent versus the Xetra close of October 13, 2026 at EUR 115.00. The bid is EUR 114.80 and the ask is EUR 115.80. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Drägerwerk stock.
What matters today
The company’s published expectations are for fiscal 2026, including currency-adjusted revenue growth of 2.0 to 6.0 percent. A next round-number level is EUR 116.00, which is 0.61 percent above the current price. The finance quote lists a price-earnings ratio of 12.58 as of October 13, 2026.
Company outlook for 2026
Drägerwerk AG & Co. KGaA’s investor-relations page lists a 2026 outlook of 5.0 to 7.5 percent for the EBIT margin, EUR 20 million to EUR 120 million for DVA and EUR 44.0 million to EUR 46.0 million for the gross margin. The same page gives an expected investment volume of EUR 110 million to EUR 130 million for 2026. The figures are presented by the company as its current fiscal-year expectations.
Drägerwerk says it develops medical and safety technology and reports approximately 16,700 employees worldwide. The company’s investor-relations materials state that it generated revenue of approximately EUR 3.5 billion in 2025 and operates in more than 190 countries. Drägerwerk’s investor-relations page provides the outlook and company information.
Market context: Market report DAX.
